On our screens:Cheap stocks by free cash flow yield
The financials
Sarepta Therapeutics, Inc. by the numbers
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $731M in Q1 2026 (quarter ended Mar 31, 2026), down 1.9% from the same quarter a year earlier. That came with net income of $331M (45% of revenue). For the full year FY2025, revenue was $2.20B (+16% year on year) and net income −$713M. Its largest region in Jun 2026 was United States at $199M, 86% of the disclosed total, well ahead of Non Us at 14%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $731M | $745M | −1.9% |
| Gross profit | n/a | $474M | n/a |
| Operating income | $358M | −$300M | to a profit |
| Net income | $331M | −$448M | to a profit |
| Diluted EPS | $2.88 | −$4.60 | to a profit |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $199M | 86% |
| Non Us | $32M | 14% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Jun 2026Total $230.6M (+0.88%)
Non Us grew +13% year on yearUnited States -2.1% year on year
Segment Latestquarter on quarteryear on year
- United States$198.6M$198.6MQoQ +5.2%year on year -2.1%+5.2%-2.1%
- Non Us$32.0M$32.0MQoQ -20%year on year +13%-20%+13%